Oksana Aron, MD

Medical Weight Loss Diet Program

“Lose up to 20 pounds per month or more”

Weight Loss Motivation. Weight Loss Results.

Dr. Aron brings you fun and important weight loss tips, exciting diet recipes, medical weight loss breakthroughs, and a steady source of weight loss motivation.

Her medical weight loss program provides real results for overweight and obese persons seeking non-surgical medical treatment, with lasting results.

WeightLossNYC, New York Medical Weight Loss Center

Call now — 718-491-5525

New Diet Drug BELVIQ Approved by FDA

Author: Oksana Aron, MD Source: Weight Loss NYC Jun 29, 2012

New Weight Loss Medication

weight loss pills
BELVIQ for weight loss

Those who are overweight or obese can look to a new weight loss drug to help them lose weight. The drug, which is to be used in addition to a reduced-calorie diet and an exercise regimen, was just approved by the FDA, although its safety and other risks have not been investigated.

From an Arena Pharmaceuticals press release:

“The FDA approval of BELVIQ is an important development for patients who struggle with obesity or are overweight with comorbidities and need help with chronic weight management beyond diet and exercise,” said Jack Lief, Arena's President and Chief Executive Officer.


As with any other weight loss drug, BELVIQ is meant to be part of a weight loss plan, which also includes a healthy diet and exercise, and is not a panacea. In clinical trials, some patients experienced such side effects as headache, dizziness, fatigue, nausea, dry mouth, and constipation. Some diabetic patients in the trial experienced hypoglycemia, headache, back pain, cough and fatigue.

Doctors will soon be able to prescribe the drug, while studies on the drug’s safety, efficacy and long-term effects are in the works.

To learn more about weight loss aids, supplements and diet plans, schedule an appointment with WeightLossNYC by calling us at 718-491-5525.



Source: Arena Pharmaceuticals, Inc.

Image: FreeDigitalPhotos.net

Labels: , , , , , , , , , , ,